Equities analysts expect that T2 Biosystems Inc (NASDAQ:TTOO) will post earnings of ($0.27) per share for the current quarter, Zacks Investment Research reports. Three analysts have made estimates for T2 Biosystems’ earnings, with the highest EPS estimate coming in at ($0.25) and the lowest estimate coming in at ($0.30). T2 Biosystems reported earnings per share of ($0.35) in the same quarter last year, which would suggest a positive year over year growth rate of 22.9%. The firm is scheduled to issue its next earnings report on Thursday, March 5th.

According to Zacks, analysts expect that T2 Biosystems will report full-year earnings of ($1.27) per share for the current fiscal year, with EPS estimates ranging from ($1.31) to ($1.25). For the next year, analysts anticipate that the company will report earnings of ($0.82) per share, with EPS estimates ranging from ($0.94) to ($0.73). Zacks’ earnings per share calculations are a mean average based on a survey of sell-side analysts that follow T2 Biosystems.

A number of analysts have recently issued reports on the stock. Zacks Investment Research raised shares of T2 Biosystems from a “sell” rating to a “hold” rating in a report on Friday, November 15th. HC Wainwright reissued a “hold” rating on shares of T2 Biosystems in a research note on Thursday, November 21st. Janney Montgomery Scott downgraded T2 Biosystems from a “buy” rating to a “neutral” rating in a research report on Tuesday, November 26th. Leerink Swann set a $5.00 price target on T2 Biosystems and gave the stock a “buy” rating in a research note on Thursday, September 12th. Finally, Canaccord Genuity reaffirmed a “buy” rating and set a $3.00 price target on shares of T2 Biosystems in a research note on Wednesday, November 13th. Six research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. T2 Biosystems presently has an average rating of “Hold” and an average target price of $5.14.

Several hedge funds have recently bought and sold shares of the business. Private Advisor Group LLC bought a new stake in shares of T2 Biosystems in the 2nd quarter worth approximately $27,000. Macquarie Group Ltd. purchased a new position in T2 Biosystems in the 2nd quarter worth $27,000. Commonwealth Equity Services LLC bought a new stake in T2 Biosystems in the third quarter worth $32,000. Tower Research Capital LLC TRC lifted its stake in T2 Biosystems by 1,217.6% in the second quarter. Tower Research Capital LLC TRC now owns 22,399 shares of the medical equipment provider’s stock worth $38,000 after purchasing an additional 20,699 shares during the last quarter. Finally, Founders Capital Management lifted its stake in T2 Biosystems by 183.3% in the third quarter. Founders Capital Management now owns 17,000 shares of the medical equipment provider’s stock worth $43,000 after purchasing an additional 11,000 shares during the last quarter. 23.60% of the stock is currently owned by hedge funds and other institutional investors.

T2 Biosystems stock opened at $1.23 on Friday. The firm’s fifty day moving average price is $1.95 and its 200-day moving average price is $1.81. The stock has a market cap of $58.35 million, a P/E ratio of -0.98 and a beta of 1.04. T2 Biosystems has a fifty-two week low of $0.52 and a fifty-two week high of $5.38.

T2 Biosystems Company Profile

T2 Biosystems, Inc, an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. It provides T2 Magnetic Resonance platform that enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, and urine.

Read More: Capital Gains Distribution

Get a free copy of the Zacks research report on T2 Biosystems (TTOO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for T2 Biosystems (NASDAQ:TTOO)

Receive News & Ratings for T2 Biosystems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for T2 Biosystems and related companies with MarketBeat.com's FREE daily email newsletter.